Scott Swindle

Oct 2, 2024 | clinicalleader.com | Dan Schell |Mike Davis |Scott Swindle |Optimizing Revenue

Webinar: Maximize Control and Transparency on the Path to Study Go-Live. Join us on October 10th to discover how Medable Studio enables rapid configuration and management across applications to accelerate study start dates, improve data accuracy, and cut costs. The session will include a live demo showcasing how Medable Studio's capabilities can enhance study efficiency, transparency, and control. Click here to learn more.

Jun 17, 2024 | clinicalleader.com | Scott Swindle

By Scott Swindle, Assistant Director & Affiliated IBC Vice Chair, Biosafety Services Recombinant DNA technologies and genetically modified biological agents are increasingly utilized across a broad spectrum of therapeutic applications, marking a significant trend in clinical trial research. These investigational products (IPs) introduce unique hazards that may not be familiar to clinical personnel responsible for their handling.

Nov 16, 2023 | clinicalleader.com | Darshan Kulkarni |Daniel Eisenman |Scott Swindle

Impact Of Research Misconduct Updates On Clinical Trial SponsorsThe Office of Research Integrity (ORI) has proposed updates to the Public Health Service Policies on research misconduct. Darshan Kulkarni outlines how the proposal should influence sponsors to reevaluate existing trial practices. Reporting Unexpected Incidents To The IBCUtilize this comprehensive guide to better understand reportable incidents and the appropriate channels for communication when unforeseen events arise.

Apr 28, 2023 | clinicalleader.com | Scott Swindle

Article | April 28, 2023 By Scott Swindle, Assistant Director, Biosafety Services Since the COVID-19 outbreak and the expedited search for a vaccine, the use of engineered genetic materials has rapidly expanded in clinical trials.